🇺🇸 FDA

Intelligence · Clinical Pipeline

Lxo Ireland Designated Pipeline

All ClinicalTrials.gov programs at Lxo Ireland Designated — phase, modality, and trial IDs.

Programs
68

Quick answer

Lxo Ireland Designated has 68 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  4. Cloxacilin

    Lxo Ireland Designated Activity Company

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

  5. Conventional medical treatment

    Lxo Ireland Designated Activity Company

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  6. Discontinuation antipsychotic treatment

    Lxo Ireland Designated Activity Company

    Psychosis Nos/Other

    phase 3 small molecule active

    1 trial

  7. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  9. Influenza vaccine

    Lxo Ireland Designated Activity Company

    Infection in Solid Organ Transplant Recipients

    phase 3 mab completed

    1 trial

  10. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  11. Levodopa

    Lxo Ireland Designated Activity Company

    Ischaemic Stroke

    phase 3 small molecule completed

    1 trial

  12. Paclitaxel-releasing PTA balloon catheter

    Lxo Ireland Designated Activity Company

    Arteriovenous Fistula Renal Dialysis Devices Obstruction

    phase 3 other completed

    1 trial

  13. Platelet rich plasma

    Lxo Ireland Designated Activity Company

    Coxarthrosis

    phase 3 small molecule completed

    1 trial

  14. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  15. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  16. Rituximab

    Lxo Ireland Designated Activity Company

    Lupus Nephritis

    phase 3 mab terminated

    1 trial

  17. Topotecan - usual

    Lxo Ireland Designated Activity Company

    SCLC

    phase 3 small molecule active

    1 trial

  18. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  19. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  20. Anterior lamellar nanostructured artificial human cornea.

    Lxo Ireland Designated Activity Company

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  21. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  22. Autologous adipose derived mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  23. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  24. Bioengineered Artificial Mesenchimal Sheet (BAMS)

    Lxo Ireland Designated Activity Company

    Venous Ulcer

    phase 2 mab active

    1 trial

  25. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  26. Bone marrow mononuclear cells

    Lxo Ireland Designated Activity Company

    Chronic Myocardial Ischemia

    phase 2 other completed

    1 trial

  27. CMB305

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 mab terminated

    2 trials

  28. Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial

  29. Combination of MK3475 with Metronomic CP

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 small molecule completed

    1 trial

  30. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

  31. DT-168

    Lxo Ireland Designated Activity Company

    Fuchs Endothelial Corneal Dystrophy

    phase 2 small molecule active

    1 trial

  32. DT-216P2

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 2 small molecule active

    2 trials

  33. G100

    Lxo Ireland Designated Activity Company

    Follicular Low Grade Non-Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  34. Gabapentin

    Lxo Ireland Designated Activity Company

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  35. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  36. IMD-1041

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  37. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  38. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial

  39. Infusion of mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Faecal Incontinence

    phase 2 small molecule completed

    1 trial

  40. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  41. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials

  42. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial

  43. Intravenous administration of 1 million of MSC

    Lxo Ireland Designated Activity Company

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  44. Mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia

    phase 2 other completed

    1 trial

  45. PHITAH

    Lxo Ireland Designated Activity Company

    Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  46. Stem cell infusion

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule terminated

    1 trial

  47. implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  48. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

Frequently asked questions

How many pipeline programs does Lxo Ireland Designated have?

68 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.